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Abstract 
It is increasingly known that gender differences affect disease presentation, clinical pathways, diagnostic yield and 
prognosis of patients with cardiovascular disorders. There are novel insights regarding heart failure that provide a platform for 
personalized medicine. This is a review of the existent data about heart failure in women, a neglected topic that has gained 
considerable interest in the past years. 
Heart failure in women differs in many aspects from that of men. Part of the difference is attributable to age, ventricular 
function and cause of heart failure, with women being generally older at heart failure onset, more often without left ventricular systolic 
dysfunction and less often having heart failure due to ischaemic heart disease, in comparison with men. Elucidation of the genetic 
and pathophysiological basis of sex differences, together with clinical trials designed to study the impact of treatments in women, 
could lead to sex based heart failure management. 
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Introduction 
If until recently, epidemiological and clinical data 
regarding cardiovascular health were extrapolated to the 
entire population, recently published studies have shown 
that there are obvious, sex related differences, in terms of 
cardiovascular disease in general and heart failure in 
particular. The idea of a personalized approach of this 
pathology came into light with the evidence of different 
gene profiles in female and male. Autosomal genes 
(GATAD1, SCLA12, PDE6B) involved in the metabolism 
of cyclic nucleotides, glucose transport and neurohumoral 
stimulation were identified in women with heart failure, 
unlike the male population with heart failure, where the 
genes responsible for arrhythmias, self immunity and 
cellular homeostasis (KCNK1, CD24, PLEKHA8) were 
overexpressed [1] (Table 1). It is believed that gender-
specific differences in gene expression may explain the 
physiopathological and clinical differences between sexes 
regarding heart failure. In this context, personalized 
medicine gained an increasing interest, the target being 
the understanding of the impact of gender differences, 
establishing a strictly individualized disease approach and 
obtaining the leads for treatment optimization. 
 
 
Table 1. Heart failure: gender-specific differences in gene expression (modified after [1,2]). 
 
WOMEN 
 
MEN 
 
Regulation in gene expression of adrenergic and 
angiotensin signaling (GATAD1) 
Regulation in gene expression of potassium channel (KCNK 1) 
Regulation in gene expression of glucose 
transporter (SLCS2A12)  
 
Autosomal gene CD24, that through its expression on leucocytes 
may have an important function in immunological 
processes  
 
Regulation in gene expression of 
phosphodiesterase (PDE6B)  
Regulation in gene expression of cellular homeostasis (PLEKHA 8) 
 
 Journal of Medicine and Life Volume 4, Issue 3, July‐September 2011 
281  © 2011, Carol Davila University Foundation
Although more than half of the patients 
diagnosed and hospitalized for heart failure are women, 
they are underrepresented in most of the clinical studies. 
Even in recent trials, only 20% of patients with heart 
failure are women. This explains the limited analysis of 
sex related differences in cardiovascular pathology [3]. 
Etiology of heart failure 
There are gender differences regarding the age 
at heart failure onset, as well as heart failure etiology and 
risk factors in patients with heart failure [4]. Unlike men 
with heart failure, in whom the ischemic etiology prevails, 
the main risk factors in women are arterial hypertension, 
valvular heart disease and atrial fibrillation [5] (Table 2). 
Women develop heart failure at higher age and 
this is why they cumulate more risk factors [6]. Many 
studies have found arterial hypertension to be the most 
important risk factor for heart failure in women. The 
significant prevalence in women over 55 years old has 
been attributed to higher systolic blood pressure after 
menopause. A strong correlation between hypertension 
and heart failure has also been observed in young afro-
American women with uncontrolled blood pressure. 
 
 
Table 2. Etiologic spectrum of heart failure in women (according to [5-12]). 
 
MAIN CAUSES 
 
 
PARTICULAR FORMS 
  Arterial hypertension 
  Diabetes mellitus 
  Obesity 
  Valvular heart disease 
  Vulnerability to ischemia 
  X-linked cardiomyopathy 
  Peripartum cardiomyopathy 
  Tako-Tsubo cardiomyopathy 
  Toxic cardiomyopathy (ethanol, antracicline) 
 
 
Diabetes mellitus is associated with an increased 
risk of heart failure in female patients, this being proved 
since the Framingham study: the incidence of heart failure 
was 4-5 times higher in diabetic women compared to non-
diabetic women and twice higher than in diabetic male 
subjects. The probability for diabetic patients to develop 
heart failure is strongly linked to the glycemic control. A 
study made on more than 48.000 diabetic patients 
showed a probability of 4.2/1000/year at a HbA1c value of 
less than 7% and a probability of 9.2/1000/year at a 
HbA1c value of more than 10% [7]. The endothelial 
dysfunction  is a characteristic of diabetes, and 
endothelium-derived substances  may have profound 
effects on myocardial structure and function. For example, 
both endothelin and angiotensin II cause myocardial 
hypertrophy and increased interstitial connective tissue, 
which can explain the higher left ventricle mass in patients 
who associate diabetes and hypertension, compared to 
nondiabetic hypertensive  patients. Therefore, it is not 
surprising that diabetes is one of the major factors, along 
with hypertension and coronary heart disease, associated 
with heart failure with normal systolic function, form 
frequently observed in women. 
Obesity, an integral component of the metabolic 
syndrome and type 2 diabetes,  predisposes to the toxic 
effects of fatty acids on the myocardium and the additional 
detrimental effects of cytokines and angiotensin  II 
released by adipose tissue. Therefore, obesity is a risk 
factor for heart failure for both men and women. In the 
Framingham study, the risk of heart failure was twice 
higher for the obese persons compared to subjects with 
normal body weight [8]. 
Valvular heart disease continues to be a cause 
of heart failure in women. According to the data published 
by Redberg et al., 70% of the patients diagnosed with 
mitral or aortic valve disease are women [9]. Rheumatic 
mitral stenosis due to rheumatic fever in childhood used 
to be a major cause of valve disease in female. This still is 
a major contributor of heart failure in some part of the 
underdeveloped world. In developed countries, a more 
common cause of heart failure is the degenerative 
valvular disease with aortic stenosis, this being the classic 
example. 
Although the incidence of coronary heart disease 
is lower in women, the increased vulnerability to ischemia 
is notable [10]. The studies have shown that, regardless 
of the type of treatment (conservative/myocardial 
revascularization), women who suffered a myocardial 
infarction are more predisposed to develop heart failure 
[11]. 
Several types of cardiomyopathy are more 
frequently linked to the female sex. It has been 
consistently seen in literature that women are very 
vulnerable to an increased level of catecholamines, 90% 
of stress induced cardiomyopathies (Tako-Tsubo) being 
registered in women. Differences between men and 
women were also described regarding cardiotoxicity. At 
similar doses of chemotherapy (anthracycline class) or 
ethanol, women have a higher risk of developing heart 
failure. 
Peripartum cardiomyopathy is a particular case 
of heart failure with an etiology that is not completely 
known, with nonspecific diagnostic criteria and reserved 
prognosis. The incidence varies according to different 
studies and has been estimated to range from 1:2300 to Journal of Medicine and Life Volume 4, Issue 3, July‐September 2011 
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1:4000 pregnancies in Western countries. A geographical 
predilection is found in Haiti, with an estimated incidence 
of 1:299. Advanced maternal age, multiparity, multifetal 
pregnancy, preeclampsia and gestational hypertension 
are mentioned among the risk factors. Recently, the 
overexpression of 16-kDa prolactin was suggested to be a 
possible physiopathological mechanism for peripartum 
cardiomyopathy [12]. This proposed pathway emphasizes 
a coincidence of unbalanced oxidative stress, activation of 
the protease cathepsin D, that cleaves the nursing 
hormone prolactin into an angiostatic and proapoptotic 
16-kDa form, which seems to drive the disease by 
systemically affecting the endothelium, as well as the 
cardiac vasculature and cardiomyocyte function. 
Consistent with this idea, blockade of prolactin by 
bromocriptine, a dopamine D2-receptor agonist, 
prevented the onset of disease in an experimental model 
of peripartum cardiomyopathy and appeared successful in 
small pilot trials. In the presence of risk factors and clinical 
suspicion in young women at the end of pregnancy or in 
the first 5 months postpartum, the diagnosis of   
peripartum cardiomyopathy, based on exclusion criteria, 
is established by ultrasound investigation once the 
systolic dysfunction appears (the decrease of the ejection 
fraction under 45% and/or fractional shortening under 
30%). The prognosis is reserved because of the limited 
recovery (23-32% of all cases) and the high mortality rate 
(15% of all cases) [12]. 
When speaking about X-linked cardiomyopathy 
in women, the slow progression and the late onset are 
remarkable features, females being heterozygote for the 
mutant allele. At the opposite pole, men with this condition 
become symptomatic since childhood. 
From the associated pathology point of view, 
thyroid dysfunction is more frequent in women with acute 
heart failure, while in men, obstructive pulmonary disease, 
peripheral vascular disease, and renal failure prevail.  
Physiopathological particularities 
There is no opinion agreement regarding the 
existence of physiopathological particularities linked to 
sex because it is difficult to exclude the variables that 
could be responsible for those particular elements. 
Starting from the observation that women have a 
higher incidence of heart failure with preserved ejection 
fraction but with reduced diastolic compliance, the issue 
of sex-related variability of cardiac function came into 
light. The answer was given by a study that analyzed the 
diastolic compliance in healthy teenagers. For female 
gender, higher body mass index, ventricular rate, total 
peripheral stiffness and relative left ventricle walls 
thickness were observed. Lower values were registered 
for the E/A ratio, suggesting that women have a higher 
probability to develop diastolic dysfunction even 
independent of the additional risk factors. The reason for 
those differences in filling and relaxation is not fully 
known. Although E/A ratio can depend on ventricular rate, 
blood pressure, geometry and left ventricular systolic 
function, the multivariate analysis showed that sex had a 
significant influence on ventricular filling [13]. 
Studies on adult patients showed, as a particular 
element in women, a higher capacity of the left ventricle to 
adapt to overload through concentric hypertrophy, unlike 
men who had a predisposition to ventricular dilation and 
contractile dysfunction [14,15]. Although the cause of this 
different response is not entirely understood, a 
reasonable explanation is offered by the sex-dependent 
variability of vascular and ventricular stiffness. There is a 
significant increase of vascular stiffness in women, with 
age. In order to maintain the optimal ventriculoarterial 
interaction, the ventricle develops increasing elasticity, 
both systolic and diastolic, which has the advantage of 
preserving the ejection fraction and the disadvantage of 
altering the relaxation. It remains a dilemma what the 
factors that determine the increase of arterial stiffness in 
women are. Among the proposed mechanisms, 
endothelium dysfunction is a notable factor, frequent in 
women, as well as the differences in protein structure and 
in neurohumoral signal [16]. 
Clinical presentation 
The severity of symptoms is one clinical 
particularity of heart failure in women. The MONICA study 
(Multinational MONItoring of trends and determinants in 
CArdiovascular disease) showed that, in similar 
contractile parameters, women are more symptomatic 
than men [17]. The prevalence and the increased severity 
of symptoms were attributed on one hand to the lower 
level of pain perception, and on the other hand to 
depression. The neurological disorders like loss of 
memory and depression were correlated to a significant 
hippocampus reduction in women with heart failure, 
compared to the control group and to male subjects with 
heart failure. Because women frequently have the 
tendency to empathize, the objective evaluation through 
clinical score systems is more difficult to achieve and the 
obtained data have usually reduced accuracy. 
Paraclinical data 
Both quantitative and qualitative analyses of 
cardiac function have been rarely evaluated in female 
subjects. It is possible to have some differences between 
sexes regarding the paraclinic data, but because of the 
less frequently used diagnostic investigations, so far they 
have not been assessed [18,19]. 
B-type natriuretic peptide, a biomarker used for 
risk stratification in patients with heart failure, registers 
higher values in normal females [20]. Therefore, the use 
of a different cutoff for the diagnosis and management of 
heart failure for the two sexes was suggested. The 
BASEL study (B-type natriuretic peptide for Acute Journal of Medicine and Life Volume 4, Issue 3, July‐September 2011 
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Shortness of Breath Evaluation), that had as main 
purpose the  analysis of the prognostic role of B-type 
natriuretic peptide (BNP) in patients with acute dyspnea, 
showed that a higher level of BNP is a stronger predictor 
of death in women. The risk was 5.1 times higher in 
women with BNP> 500 pg/ml than in those with BNP 
values below 500 pg/ml, and for similar BNP values in 
men, the difference in risk was of only 1.8 [21]. However, 
further studies that enroll a sufficient number of female 
patients are needed to analyze the distribution of heart 
failure biomarkers and its prognostic significance. 
The  electrocardiogram is among the first tests 
available for the evaluation of postmenopausal women. 
Repolarization abnormalities are prognostic predictors of 
heart failure and all-cause mortality, as significant as the 
presence of an old myocardial infarction on ECG; 
therefore, this should not be overlooked. The presence of 
repolarization abnormalities, particularly wide QRS/T 
angle, may make a substantial difference in the number of 
new heart failure events and may warrant consideration of 
possibly intensified prevention efforts. A wide angle, 
expression of structural and functional myocardial 
abnormalities, increases the risk of heart failure by three 
times. Two other dominant repolarization variables, ST 
depression in V5, tall T wave in V1 lead, and QRS non-
dipolar voltage were associated with a 2-fold increase in 
the risk of incident heart failure having the same 
prognostic value as a myocardial infarction [22]. 
Through the analysis of heart frequency 
variability, the ECG Holter monitoring may bring 
information with prognostic value. There are studies that 
showed a strong correlation between a high variability of 
ventricular rate and heart failure [22]. 
The effort capacity, evaluated through the 6-
minute walk test is significantly higher in men with heart 
failure, compared to women with similar systolic 
dysfunction. In the First study, the effort tolerance and the 
mean pulmonary capillary wedge pressure proved to be 
independent predictors for survival in patients with heart 
failure [23]. 
From the echocardiography point of view, the 
preservation of left ventricular systolic function is 
characteristic in women with heart failure. This was also 
the conclusion of the Framingham study, which showed 
that women represent 65% of patients with diastolic heart 
failure and only 25% of those with systolic dysfunction. 
Diagnosis algorithm of heart failure in 
women 
Studies show that the accuracy of heart failure 
diagnosis by clinical means alone is often inadequate, 
particularly in women. The diagnosis is established late in 
most of the female patients, clinical manifestations being 
attributed to other causes. Women were less likely to be 
hospitalized in a cardiology department and therefore 
have less chances of accurate assessment of cardiac 
function. In these circumstances, it is not surprising that 
heart failure in women is treated to a lesser extent 
according to present recommendations [24]. 
In the context of reduced BNP dynamics, 
preserved ejection fraction and normal ventricular 
dimensions, heart failure is frequently underdiagnosed in 
women. Because of the high diastolic heart failure 
prevalence, it is necessary to know the three diagnostic 
elements: signs and symptoms of heart failure, normal left 
ventricle function or marginally abnormal (FEVS>50%), 
proofs of abnormal left ventricular relaxation [25]. The 
authors of the European Consensus regarding the 
diagnostic of heart failure with preserved ejection fraction 
[26], published in 2007, proposed a comprehensive 
algorithm for the clinical approach of this entity (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Diagnostic flowchart on ‘How to diagnose HFNEF’ in a patient suspected of HFNEF (according to [26]). LVEDVI, left 
ventricular end-diastolic volume index; mPCW, mean pulmonary capillary wedge pressure; LVEDP, left ventricular end-diastolic 
pressure; t, time constant of left ventricular relaxation; b, constant of left ventricular chamber stiffness; TD, tissue Doppler; E, 
early mitral valve flow velocity; E0, early TD lengthening velocity; DT, deceleration time; LVMI, left ventricular mass index; LAVI, 
left atrial volume index; Ard, duration of reverse pulmonary vein atrial systole flow; Ad, duration of mitral valve atrial wave flow, 
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Treatment 
The therapy particularities in women were for a 
long time underestimated due to their absence from the 
big therapy trials. When women were included in studies, 
their number was significantly lower compared to men, 
and therefore the conclusions were incorrect, e.g. the 
modest benefit of angiotensin-converting enzyme 
inhibitors in female patients in SOLVD trial. This is one of 
the explanations for the suboptimal treatment in women 
with heart failure, regardless of age [27]. More men are 
treated with angiotensin-converting enzyme inhibitors, in 
part reflecting the high proportion of men with systolic 
dysfunction. A multicentric European study showed that 
fewer women with evidence of left ventricular systolic 
dysfunction were treated with drugs that have a 
documented impact on survival (angiotensin-converting 
enzyme inhibitors, β-blockers and spironolactone), 
whereas they receive more often cardiac glycosides and 
loop diuretics [28]. 
An inverse correlation between plasma levels of 
omega-3 polyunsaturated fatty acids and incidence of 
heart failure was detected exclusively in women [29]. 
Moderate consumption of fish (1-2 meals/week) and 
omega-3 fatty acids was associated with a lower rate of 
hospitalization and mortality in women with heart failure 
[30]. 
Knowing the protective effect of hormones, the 
treatment with estrogen and combination estrogen-
progesterone derivatives has been proposed. However, 
hormonal therapy has not proved effective in preventing 
heart failure or increasing survival [31]. Starting from the 
premise of muscle loss and reduced exercise capacity, 
testosterone treatment has been tried. In clinical trials, the 
results were encouraging, proving to increase muscular 
strength, and exercise tolerance and to reduce insulin 
resistance in women with advanced heart failure [32].  
In a retrospective analysis of the SOLVD trial, 
women with heart failure had an increased risk of 
thromboembolic events compared with men. Although 
women have experienced more thromboembolic events 
(especially pulmonary), antiplatelet therapy and oral 
anticoagulant has been less frequently used in women 
[33]. 
A sub-analysis of MADIT-CRT trial has revealed 
that women with heart failure have a particularly favorable 
response to cardiac resynchronization therapy with 
defibrillator function. Heart failure related events were 
reduced by 70% in women and only 35% in men. The 
same study showed a 72% reduction in all-cause mortality 
in women with heart failure who received 
resynchronization therapy with defibrillator function. An 
update of the 2008 ESC guidelines for the diagnosis and 
treatment of acute and chronic heart failure, and the 2007 
ESC guidelines for cardiac and resynchronization therapy, 
sustain that substantial improvements in left ventricle size 
and function were greatest in patients with a QRS width of 
≥150 ms, patients with left bundle, patients with non-
ischaemic etiology, and in female patients [34], hence 
suggesting that a good accessibility of women to this 
therapy would be of great benefit in this population. 
Another recent report described that heart failure 
medication was not prescribed to target dose as 
recommended in the guidelines. Here, physician gender 
also played a role, with female patients treated by male 
physicians being least likely to receive the full dosage, 
and female doctors being more likely to prescribe target 
doses of heart failure medication to female patients [35]. 
There are also gender differences regarding 
drug pharmacokinetics and pharmacodynamics. If the 
absorption, transport and volume of distribution did not 
differ significantly between women and men with heart 
failure, excretion and metabolism explains their different 
effects depending on gender. On average, glomerular 
filtration rate (GFR) is higher in men than in women. This 
difference is not gender-related; rather, it represents a 
body mass effect, in that GFR is directly proportional to 
weight and men typically outweigh women. In addition, 
women generally produce less creatinine than men, since 
they have less muscle mass, and muscle mass is the 
major determinant of creatinine generation. It follows that 
women have a lower normal range for serum creatinine 
values and that identical serum creatinine values in a man 
and a woman reflect considerably different GFRs. 
Circumstances such as these make serum creatinine a 
provisional indicator of renal function. Because GFR 
values are somewhat lower in women, a number of 
cardiovascular medications—including angiotensin-
converting enzyme inhibitors, certain β blockers, several 
antiarrhythmics, and digoxin will systemically accumulate 
upon repeat dosing unless medication doses are reduced. 
Supplementary, the metabolic rate of drugs 
through the cytochrome P450 is reduced in female 
patients.  In this context, we need to assess the 
complications associated with the pharmacological 
treatment that are more frequently reported in women. 
These differences are especially evident in the risk of 
proarrhythmic responses of women to medications that 
prolong the QT interval. Women are at greater risk for 
torsade de pointes from antiarrhythmic medications due to 
longer baseline QT intervals, than men, and a greater 
degree of QT prolongation for the same drug levels 
compared with men.  Despite careful dosing based on 
creatinine clearance, the incidence of torsade de pointes 
with dofetilide is higher in women than in men. 
Regardless, there are no gender-specific guidelines for 
the administration of these agents. Therefore, there is 
evidence that the commonly used indicators of risk for 
malignant arrhythmias may be less sensitive for women 
than for men. The question may then be raised whether 
separate criteria are needed for risk stratification and 
treatment of arrhythmias in men and women. The answer 
to this question is far from clear —largely due to the 
limited data. Furthermore, female-specific issues such as Journal of Medicine and Life Volume 4, Issue 3, July‐September 2011 
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pregnancy, menopause, oral contraceptive use, and 
menstruation may independently influence drug 
metabolism and serve as confounders to the 
interpretation of gender differences in drug handling or 
effect [36]. 
With the discovery of prolactin effects on the 
cardiovascular system: the impairing of remodelation and 
vascular formation, the destruction of cardiac 
microvascularization, the interference with cardiomyocyte 
metabolism, the decrease of the ejection fraction and 
ventricular dilatation, appeared the premises of the new 
therapy approach. Based on experimental observations 
that prolactin blockade with bromocriptine prevented the 
onset of peripartum cardiomyopathy, a specific treatment 
for these diseases has been developed [12]. 
Females are also poorly represented in cardiac 
rehabilitation programs. The low participation is attributed 
to older age, reduced tolerance to effort and associated 
comorbidities. Studies have shown the existence of socio-
familial differences, which could explain the low number of 
women who benefit from cardiac rehabilitation: women 
have more family and social duties, but more difficulties in 
terms of financial resources, transport, or family support. 
However, no sex-dependent differences in relation to the 
benefit of cardiac rehabilitation were demonstrated. 
Cautions 
Pregnancy may lead to deterioration of heart 
failure due to the rise in blood volume and increase in 
cardiac output, as well as the  substantial increase in 
extravascular fluid. The risk of pregnancy is considered 
greater than the risks linked to contraceptive use. It is 
recommended that women with heart failure discuss 
contraceptives and planned pregnancy with a physician in 
order to take an informed decision based on assessment 
of potential risks (class I recommendations, C level of 
evidence: ESC Guidelines for the diagnosis and treatment 
of acute and chronic heart failure 2008). 
Prognosis 
Heart failure has become the most important 
public health problem in cardiovascular medicine. The 
incidence of heart failure has increased with 9% in women 
and 6% in men during the last 20 years [37]. Mortality at 5 
years after diagnosis reached 75%, being surpassed only 
by the one registered in bronchopulmonary cancer. 
The FIRST trial (Flolan Randomizen Survival 
Trial) showed a two times higher rate of survival for 
women with advanced heart failure compared to men. 
Female sex has favorable prognosis regarding all-cause 
mortality, cardiovascular related death and hospitalization 
for heart failure. Subgroup analysis suggests this finding 
is strongest among patients with heart failure with 
preserved ejection fraction and in patients with 
nonischemic heart failure. Better understanding of the 
biological and psychosocial factors that contribute to the 
survival advantage of women with heart failure may 
ultimately allow improved management of patients with 
this deadly syndrome. 
Conclusions 
For a long period of time, women have been 
profoundly underrepresented in clinical trials, and the 
influence of sex on cardiovascular pathophysiology was 
neglected. Recent studies showed significant differences 
between men and women with heart failure. Although, 
more clinical trials are needed in this field, the current 
tendency towards a similar approach to all patients with 
heart failure has to be changed. 
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